SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: sam who wrote (3759)2/10/1998 8:32:00 AM
From: Henry Niman  Read Replies (1) of 6136
 
sam, Here's a more positive article put out by the San Diego Union Tribune:

Agouron's AIDS drug may set record

DON BAUDER
08-Feb-1998 Sunday

Sales of Agouron's Viracept treatment for AIDS "may set a record for
first-year sales of a biotechnology product," says Jim McCamant of
Berkeley's Medical Technology Stock Letter.

The product was launched in mid-March of last year; it chalked up sales of
$228 million during the rest of 1997, says McCamant. Sales were $91.8
million in the quarter ended in December. For the full fiscal year, which
ends in June, the product should enjoy sales of $350 million, says the
analyst.

"This makes current market capitalization of $1.06 billion only three times
sales for the current fiscal year," he says, noting that Agouron beat a
competitor to market by 18 months. A couple of years ago, McCamant had said
that the competitor was ahead of Agouron. He would buy the stock under $40.
It has been trading around $35.

Elise Wang of PaineWebber says that Agouron's Viracept has 36 percent of
its market, and is the leader in dollar sales. "Viracept is being
considered as the optimal first line of therapy," says Wang. Looking for
the company to earn 98 cents a share in the current fiscal year,
PaineWebber has the stock on its Analysts' Best Calls list.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News